OpenAI Acquires Orchestra Bio to Expand Life Sciences AI Capabilities
OpenAI has acquired Orchestra Bio, an AI biotech software startup, to accelerate its Rosalind life sciences research platform and compete in pharmaceutical automation.
OpenAI has acquired Orchestra Bio, an AI biotech software startup, to accelerate its Rosalind life sciences research platform and compete in pharmaceutical automation.
OpenAI has acquired Orchestra Bio, a platform for coordinating biopharma R&D, integrating it with Rosalind, its life sciences AI suite.
OpenAI is offering free access to GPT-Rosalind and its specialized workbench to eligible academic labs for up to 12 months, including 30 complimentary Business Standard seats.
Anthropic debuts Claude Science, a standalone product for computational biology and drug discovery, positioning itself as a serious contender in scientific AI.
Anthropic launches Claude Science, a dedicated AI workbench for scientific research that integrates databases and enforces reproducibility—without releasing a new model.
OpenAI released LifeSciBench, a benchmark designed to measure whether AI systems can handle real-world life science research workflows, not just answer biology questions.